Expertise in
26
conditions

Dr. Adam J. Olszewski

Hematology
Rhode Island Hospital
593 Eddy St, 
Providence, RI 
Offers Telehealth
Expertise in
26
conditions
Rhode Island Hospital
593 Eddy St, 
Providence, RI 

Overview

Adam Olszewski is a Hematologist practicing medicine in Providence, Rhode Island.

Dr. Olszewski is highly rated in 26 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, Splenectomy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 388 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in RI

Hospital Affiliations

Rhode Island Hospital
Newport Hospital
The Miriam Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Rhode Island Hospital
593 Eddy St, Providence, RI 02903

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drugs: CDX-1140, CDX-301, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Drug
Study Drugs: Rituximab, Bendamustine, Vincristine sulfate
Study Phase: Phase 1
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: April 13, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

388 Total Publications

Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.
Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.
Journal: AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science
Published: June 19, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Expertise in
6
conditions
Dr. Patrick T. Mcgann
Hematology | Oncology
Expertise in
6
conditions
Dr. Patrick T. Mcgann
Hematology | Oncology
Referral may be required

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (0.1 miles away)
401-444-5241
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Mcgann is a Hematologist and an Oncologist practicing medicine in Providence, Rhode Island. Dr. Mcgann is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Anemia, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Mcgann is currently accepting new patients.

Frequently Asked Questions about Dr. Adam J. Olszewski

How do I make an appointment with Dr. Adam J. Olszewski?

You can book an appointment with Dr. Adam J. Olszewski by calling their office at 401-444-5435. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adam J. Olszewski a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adam J. Olszewski is classified as an Elite expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adam J. Olszewski specialize in?

While Dr. Adam J. Olszewski is a Hematology, they have specific expertise in B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Adam J. Olszewski participate in research or clinical trials?

Yes. Dr. Adam J. Olszewski has published 388 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Dr. Adam J. Olszewski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adam J. Olszewski accept my insurance?

Dr. Adam J. Olszewski accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 401-444-5435 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Olszewski's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile